The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Abstract
PURPOSE: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell safety and efficacy in patients with r/r T-ALL. METHODS: In this single-center, phase I trial, we administered anti-CD7 CAR T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with r/r T-ALL, in single infusions at doses of 5 × 10 5 or 1 × 10 6(±30%) cells per kilogram of body weight. The primary end point was safety with efficacy secondary. RESULTS: Twenty participants received infusions. Adverse events including cytokine release syndrome grade 1-2 occurred in 90% (n = 18) and grade 3-4 in 10% (n = 2), cytopenia grade 3-4 in 100% (n = 20), neurotoxicity grade 1-2 in 15% (n = 3), graft-versus-host disease grade 1-2 in 60% (n = 12), and viral activation grade 1-2 in 20% (n = 4). All adverse events were reversible, except in one patient who died through pulmonary hemorrhage related to fungal pneumonia, which occurred at 5.5 months, postinfusion. Ninety percent (n = 18) achieved complete remission with seven patients proceeding to stem-cell transplantation. At a median follow-up of 6.3 months (range, 4.0-9.2), 15 remained in remission. CAR T cells were still detectable in five of five patients assessed in month 6, postinfusion. Although patients' CD7-positive normal T cells were depleted, CD7-negative T cells expanded and likely alleviated treatment-related T-cell immunodeficiency. CONCLUSION: Among 20 patients with r/r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile. A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress ( NCT04689659 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“Characteristic All (N 5 20) Previous SCT Donor, 5 3 10(5) (6 30%)/kg (n 5 4) Previous SCT Donor, 1 3 10(6) (6 30%)/kg (n 5 8) New Donor, 1 3 10(6) (6 30%)/ kg (n 5 8) Median age, years (range) 11 (2-43) 9 (4-18) 17 (6-33) 10 (2-43) Male, No.”
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S. C., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900386 · Cited by 1,215
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., Rouce, R. H., Bao, G., Brenner, M. K., & Mamonkin, M. (2017) · Blood · doi:10.1182/blood-2017-01-761320 · Cited by 462
Marks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G., DeWald, G., Ferrando, A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 401
An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0065-5 · Cited by 392
A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015) · Blood · doi:10.1182/blood-2015-02-629527 · Cited by 335
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C.-H. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 291
Marasco, W. A., Haseltine, W. A., & Chen, S. Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7889 · Cited by 268
Pui, C.-H., Pei, D., Coustan-Smith, E., Jeha, S., Cheng, C., Bowman, W. P., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Inaba, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70082-3 · Cited by 207
A systematic review of transfusion-associated graft-versus-host disease
Kopolovic, I., Ostro, J., Tsubota, H., Lin, Y., Cserti-Gazdewich, C. M., Messner, H. A., Keir, A. K., DenHollander, N., Dzik, W. S., & Callum, J. (2015) · Blood · doi:10.1182/blood-2015-01-620872 · Cited by 205
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K.-W., Jares, A., Firor, A. E., Shuai, X., Salman, H., Golightly, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.8 · Cited by 184
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Pan, J., Zuo, S., Deng, B., Xu, X., Li, C., Zheng, Q., Ling, Z., Song, W., Xu, J., Duan, J., et al. (2020) · Blood · doi:10.1182/blood.2019003293 · Cited by 160
Self-citationExpression and function of CD7 molecule on human natural killer cells.
Rabinowich, H., Pricop, L., Herberman, R. B., & Whiteside, T. L. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.517 · Cited by 137
CD7- T cells represent a subset of normal human blood lymphocytes
Reinhold, U., Abken, H., Kukel, S., Moll†, M., Müller, R. H., Oltermann, I., & Kreysel, H. W. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.5.2081 · Cited by 104
CD7 Is a Differentiation Marker That Identifies Multiple CD8 T Cell Effector Subsets
Aandahl, E. M., Sandberg, J. K., Beckerman, K., Taskén, K., Moretto, W. J., & Nixon, D. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2349 · Cited by 87
Candoni, A., Lazzarotto, D., Ferrara, F., Curti, A., Lussana, F., Papayannidis, C., Principe, M. I. D., Bonifacio, M., Mosna, F., Delia, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25957 · Cited by 73
Immunologic Characterization of CD7-Deficient Mice
Lee, D. M., Staats, H. F., Sundy, J. S., Patel, D. D., Sempowski, G. D., Scearce, R. M., Jones, D. M., & Haynes, B. F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5749 · Cited by 67
Pan, J., Tan, Y., Deng, B., Tong, C., Hua, L., Ling, Z., Song, W., Xu, J., Duan, J., Wang, Z., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0831-z · Cited by 67
Self-citationReedijk, A., Coebergh, J. W. W., de Groot‐Kruseman, H. A., van der Sluis, I. M., Kremer, L. C. M., Karim‐Kos, H. E., & Pieters, R. (2020) · Leukemia · doi:10.1038/s41375-020-01024-0 · Cited by 46
Targeted gene disruption of murine CD7
Bonilla, F. A. (1997) · International Immunology · doi:10.1093/intimm/9.12.1875 · Cited by 41
Cited by
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 352
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300709 · Cited by 340
Metadata
- Authors
- Pan, J., Tan, Y., Wang, G., Deng, B., Ling, Z., Song, W., Seery, S., Zhang, Y., Peng, S., Xu, J., Duan, J., Wang, Z., Yu, X., Zheng, Q., Xu, X., Yuan, Y., Yan, F., Tian, Z., Tang, K., Zhang, J., Chang, A. H., & Feng, X.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-10-20
- Volume
- 39
- Issue
- 30
- Pages
- 3340-3351
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3185250096
- Cited by
- 300
- References
- 26
- FWCI
- 17.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.